Aspen concludes strategic M.O.U with the Russian Federation

Windhoek, Namibia – JSE Limited listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has announced that a memorandum of understanding (“M.O.U”) has been concluded between Aspen’s Russian business and the Vladivostok Far Eastern Federal University (“F.E.F.U”). The Deputy Prime Minister of Russia Mr. Yury Trutnev, who has delegated authority from the Russian President for the Far Eastern Federal Region of Russia, oversaw proceedings and committed the region and university to this collaborative effort.

Stavros Nicolaou, Aspen Senior Executive Strategic Trade Development said, “The Group welcomes this latest collaboration with the Russian Federation which further complements existing relations with that country. The M.O.U provides for cooperative efforts to improve the quality of education and contribute towards advanced innovative technology in the fields of thrombosis and anaesthesia through joint training and research efforts with the FEFU. The goal of the programme is to decrease the mortality rate of thrombotic events and to increase the quality of anaesthesia use in the Russian Federation. This will improve the life expectancy of Russian citizens in the medium to long term, as clinicians will have access to some of the newest low molecular weight heparin technology, which has an improved safety profile against older interventions.”

Aspen was established in the Russian Federation in 2013 and employs over 150 specialist representatives  detailing critical medicine areas that include anti-thrombosis and anaesthesiology.

One of the principle products in Aspen’s thrombosis therapeutic portfolio is Fraxiparine (Nadroparine Calcium), which substantially diminishes the risk of the formation of life-threatening blood clots. This low molecular weight heparin is manufactured through a complex process and provides one of the best in class safety and efficacy anti-thrombotic profiles. Aspen is in discussion with the Ministry of Health for the inclusion of Fraxiparine on the Russian Federation Essential Drug List. The use of anti-thrombotic agents in the Russian Federation is approximately 10% of that of the European Union.

In 2015 Aspen commenced technology transfer for the Russian-based manufacture of Fraxiparine through its Russian partner Nanolek L.L.C, which is in the Kirov region of Russia.  Aspen’s products are distributed throughout the Russian Federation.










Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.